Objective To explore the influence of intermittently inhaled budesonide on wheezing improvement and recurrent in infants,assess their body height and weight development status.Methods 138 wheezing infants were selected.They were randomly divided into the treatment group and the control group,69 children in each group.The treatment group received budesonide therapy when upper respiratory infection symptoms infection,the control group was given ribavirin injection spray treatment.After two weeks treatment,the number of severe wheezing and systemic corticosteroids were observed,the asthma relapse frequency in one year and height and weight were assessed.Results The severe wheezing number and the application of systemic corticosteroids number of the treatment were 1 case (1.50%)and three cases (4.35%),which were lower than the control group 8 cases (11.59%)and 11 cases (15.94%).The difference was statistically significant (χ2 =8.71,P <0.05).The frequency of wheezing within one year of the treatment group was (2.39 ±0.41)times,which was lower than (4.56 ±0.45)times of the control group, the difference was statistically significant (t =9.06,P <0.05).Comparison of height and weight of the two groups after one year,the differences was not statistically significant (t =1.45,1.18,all P >0.05).Conclusion Budesonide in the treatment of intermittent wheezing infants can significantly improve the wheezing and reduce the use of systemic corticosteroids,reduce the relapse rate.It has no effect on the growth and development of infants.

Objective:To investigate the expression level of circular RNA circ_0020123 in ovarian cancer (OC) , and then to evaluate the diagnostic value of circ_0020123 level in ovarian cancer.Methods:Fifty-five ovarian cancer patients who were diagnosed and treated in Hangzhou Linping District Maternal and Child Health Hospital from Oct. 2016 to Mar. 2017 were selected, and serum was collected for high-throughput gene expression sequencing analysis. The circ_0020123 level in serum of ovarian cancer patients and healthy controls was determined by real-time quantitative PCR, and the diagnostic efficacy of circ_0020123 level on ovarian cancer was evaluated by drawing receiver operating characteristic curve (ROC) . The correlation between the expression of circ_0020123 and the clinical characteristics of ovarian cancer patients was investigated by t-test. The survival curve was drawn to analyze the relationship between the serum circ_0020123 level and the prognosis and survival of ovarian cancer patients. Western blot was used to detect the expression levels of autophagy-related proteins LC3-II/LC3-I and p62.Results:Compared with the serum of healthy people (1±0.25) , the expression of circ_0020123 was significantly up-regulated in the serum of ovarian cancer patients (1.24±0.23) ( t=5.23, P<0.001) . The ROC curve showed that circ_0020123 had high diagnostic performance for the detection of ovarian cancer specimens (AUC=0.7579, P<0.001) . Comprehensive analysis of t test and logistic analysis showed that the high expression of circ_0020123 was significantly correlated with FIGO stage ( t=5.46, P<0.001) and tumor size ( t=6.37, P<0.001) . The measurement of survival data showed that the 5-year overall survival of the circ_0020123 high expression group was significantly shorter than that of the circ_0020123 low expression group ( P=0.019) . Knockdown of circ_0020123 in cells down-regulated the expression of autophagy-related proteins LC3-II/LC3-I (0.45±0.05) ( t=9.31, P=0.001) , and up-regulated the expression of p62 (1.94±0.11) ( t=12.62, P<0.001) . Conclusion:The results of this study indicate that circ_0020123 is an important ovarian cancer-related circular RNA, which provides a potential diagnostic, prognostic biomarker and therapeutic target for ovarian cancer patients.